Seattle Genetics, Genmab Form ADC Pact
The biopharmaceutical companies, Seattle Genetics and Genmab A/S, have formed an additional antibody-drug conjugate (ADC) collaboration with potential value of more than $200 million.
Under the new agreement,
â€‹Seattle Genetics is a biotechnology company focused on the development and commercialization of antibody-based therapies for the treatment of cancer, including ADCs. Its lead product, Adcetris (brentuximab vedotin), is an ADC that, in collaboration with
Genmab specializes in the development of differentiated human antibody therapeutics for the treatment of cancer. It has one marketed antibody, Arzerra (ofatumumab), for the treatment of certain chronic lymphocytic leukemia indications and a clinical pipeline with both late- and early-stage programs. Its technology base consists of the DuoBody platform for the generation of bispecific antibodies, and the HexaBody platform, which creates effector function enhanced antibodies.
Source: Seattle Genetics